Reistone Biopharma, a Shanghai startup, announced FDA approval to start a US Phase II clinical trial of a Janus Kinase 1 inhibitor (JAK1) in patients with ulcerative colitis. Reistone said the approval is a first step towards a simultaneous clinical testing of the candidate in China, the US and several EU countries. Reistone in-licensed the JAK1 inhibitor from Jiangsu Hengrui, which also backs Reistone. Formed in January 2018, Reistone focuses on globalizing innovative drugs developed in China by companies like Hengrui.
Source: China Biotoday
